In 2009, the FDA approved pazopanib as a multikinase inhibitor against VEGFR-1/2/3, PDGFR-α/β, and c-Kit receptors for the treatment of patients with advanced RCC (155). The gene discussed is FLT1; the disease is renal cell carcinoma.